Navigation Links
Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer

ompared with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin (42%/33%), brain (11%/9%), lung (11%/8%), spinal cord (4%/3%), and bone (4%/5%) in the ERBITUX and radiation versus radiation alone arms, respectively.

The incidence of Grade 3 or 4 late radiation toxicities were generally similar between the radiation therapy alone and the ERBITUX plus radiation therapy arms.

The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) were mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX as a single agent (N=103) were acneform rash (76%), asthenia (45%), pain (28%), fever (27%) and weight loss (27%).

The most common adverse events seen in patients with mCRC receiving ERBITUX with irinotecan (n=354) or ERBITUX as a single agent (n=420) were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%).

ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. Im
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/17/2014)... 17, 2014  NuView Life Sciences, Inc. (NuView) ... collaboration agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) ... diagnostic biomarker to detect cancers of the breast ... future diagnostic-imaging applications. NuView retains all rights for ... in-vitro urine screen applications. Under the ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... announced that it has earned a $4 million ... AKAO ) associated with the initiation of a ... serious multi-drug resistant (MDR), gram-negative bacterial infections.  The ... study to evaluate the efficacy and safety of ...
(Date:9/17/2014)...  Trovagene, Inc., (NASDAQ:   TROV) a developer of ... , Ph.D., has joined the Company,s Scientific Advisory Board. ... in the kinase genes that are associated with colorectal ... Department of Oncology, Torino Medical School, Institute for Cancer ... "Alberto,s work in cancer genomics has had ...
Breaking Medicine Technology:NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 2Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 3
... global provider of advanced analytical instruments for laboratories and ... MultiTek(TM) testing system for the fast, accurate detection of ... include BioFuels, Chemicals, Food & Beverage, Manufacturing and Assembly, ... is the only instrument on the market that combines ...
... personalized medicine advances will create therapies that are so effective, ... to gain access, the inventor of the DNA gene sequencer ... Personalized Health Care National Conference . , ... said personalized medicine,s first "killer apps" - therapies that will ...
Cached Medicine Technology:New ANTEK MultiTek(TM) by PAC Provides Fast, All-in-One Testing for Sulfur, Nitrogen, Halides 2Personalized Medicine 'Killer Apps' Will Transform Care Model 2
(Date:9/17/2014)... Dr. Shervin Naderi, MD, FACS, one of the ... recipient of the 2014 Vitals Top 10 Doctor Award. This ... as it honors physicians that have earned the highest patient ... by his plastic surgeon colleagues as “The Nose Man,” is ... surgeons in the world. He is the founder of ...
(Date:9/17/2014)... September 17, 2014 Promising new research ... sheds more light on the potential ability of ketones ... disease dementia. The study shows that ... be caused by impaired glucose uptake and/or utilization, and ... brain function. , The study, by the Research Center ...
(Date:9/17/2014)... 2014) A study led by St. Jude Children,s ... threshold below which male childhood cancer survivors are ... appears in September 17 edition of the journal ... patients are at highest risk for reduced sperm ... eventually increase use of pre-treatment fertility preservation methods ...
(Date:9/17/2014)... leads to an explosion of flavours in your mouth. Researchers ... can mimic what happens in your mouth when you drink ... dryness in the wine. , When wine growers turn their ... processes to bring out the desired flavour in the product ... of the taste is known in wine terminology as astringency, ...
(Date:9/17/2014)... Los Angeles, CA (PRWEB) September 17, 2014 ... Indian news outlet, tells of a 24-year-old man named Advait ... severe back pain caused by degenerative disc disease. This ... putting pressure on his nerve roots and causing severe ... degenerative disc disease and how it can lead to ...
Breaking Medicine News(10 mins):Health News:Vitals Honors Dr. Shervin Naderi With Top 10 Doctor Award 2Health News:Vitals Honors Dr. Shervin Naderi With Top 10 Doctor Award 3Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Improved risk identification will aid fertility preservation in young male cancer patients 2Health News:Improved risk identification will aid fertility preservation in young male cancer patients 3Health News:Nanoscience makes your wine better 2Health News:Nanoscience makes your wine better 3Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 2Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 3
... reactions to a,prescribed medication send more than 175,000 older ... used medications -- almost all,of them for heart disease ... March 2008 issue of the Harvard Heart Letter offers ... Warfarin: Check your bleeding time (INR) regularly. Take ...
... and Amortization Increased ... 3.85% and 2.96%, Respectively, MEXICO CITY, ... "the Group"), one of the leading Mexican,distributors of pharmaceutical products, ... other products,announces its consolidated financial and operating results for the ...
... is a,statement by William V. Corr, Executive Director, ... restaurants, bars and gaming,facilities, will be smoke-free beginning ... the Legislature last week and signed,into law today ... have delivered a historic victory for public health ...
... West announced today,that one of the country,s most iconic ... The Shops at The Bravern in downtown Bellevue as ... the needs of approximately 2,300,Microsoft employees who will be ... this fall., DavidBartonGym will offer Barton,s world renowned ...
... Over 200,of MemorialCare,s top leaders will participate in ... Habitat for Humanity of Orange County. The,home will be ... cerebral palsy and is confined to a wheelchair. Halls ... will be given a "makeover" with,upgrades throughout., (Photo: ...
... patient acceptance and ... ... that treats acute and chronic constipation, may be an,effective option for ... PEG 3350 products. Marketed in the,U.S. by Cumberland Pharmaceuticals, Kristalose(R) is ...
Cached Medicine News:Health News:Tips for Troublesome Medications, From the Harvard Heart Letter 2Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 2Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 4Health News:Nebraska's New Smoke-Free Law is Historic Win for Health 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 3Health News:MemorialCare Sponsors Habitat for Humanity Santa Ana Home 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 3
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: